CBX1 and breast cancer: Of noteworthy, the results demonstrated that CBX1 high expression was significantly correlated to shorter RFS in patients who have received adjuvant chemotherapy only (HR=1.36, p=0.045), indicating a potential role of CBX1 in contribution to chemoresistance in BC (Figure 3H).